Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-17
2005-05-17
Travers, Russell (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S050000, C514S365000, C514S307000, C514S253010
Reexamination Certificate
active
06894068
ABSTRACT:
The present invention provides compositions and methods for the treatment of HIV infection. In particular, the present invention provides non-nucleoside inhibitors of reverse transcriptase (RT), as well as methods to treat HIV infection using these non-nucleoside inhibitors of RT. In preferred embodiments, the present invention provides a novel class of substituted benzimidazoles, effective in the inhibition of human immunodeficiency virus (HIV) RT.
REFERENCES:
patent: 3825537 (1974-07-01), Haugwitz et al.
patent: 4214089 (1980-07-01), Fenichel et al.
patent: 4434288 (1984-02-01), Wike
patent: 4912219 (1990-03-01), Manoury et al.
patent: 5217984 (1993-06-01), Monforte et al.
patent: 5356917 (1994-10-01), Panetta
patent: 5360795 (1994-11-01), Townsend et al.
patent: 5468765 (1995-11-01), Banks et al.
patent: 5545653 (1996-08-01), Miller et al.
patent: 5606060 (1997-02-01), Pommier et al.
patent: 5622960 (1997-04-01), Pommier et al.
patent: 5712255 (1998-01-01), Townsend et al.
patent: 5747520 (1998-05-01), Pommier et al.
patent: 5821242 (1998-10-01), Colacino et al.
patent: 0471991 (1992-02-01), None
patent: 2092648 (1972-01-01), None
patent: 2096648 (1972-01-01), None
patent: WO 9410175 (1994-05-01), None
patent: WO 9508540 (1995-03-01), None
patent: WO 9519772 (1995-07-01), None
patent: WO 9725337 (1997-07-01), None
patent: WO 9855120 (1998-12-01), None
Roth et al.,J. Medicinal Chem., 40(26):4199-4207 (1997).
Balzarini et al.,Proc. Natl. Acad. Sci. USA, 89:4392-4396 (1992).
Boyer et al.,J. Virol., 67:2412-2420 (1993).
Buckheit et al.,Antiviral Res., 21:247-265 (1993).
Buckheit et al.,Antiviral Res., 26:117-132 (1995).
Chimirri et al.,Il Farmaco, 46:817-823 (1991).
Chimirri et al.,Il Farmaco, 46:925-933 (1991).
Chimirri et al., “Thiazobenzimidazoles as Non-Nucleoside HIV-1 RT Inhibitors”, Abs. Il Congresso Congiunto Italiano-Spagnolo di Chemica Farmaceutica, Aug. 30-Sep. 3, (1995), ML20.
Cloyd,Medical Microbiology, University of Texas Medical Branch at Galveston, pp. 761-775 (1996).
De Clercq,Biochem. Pharm., 47:155-169 (1994).
Ding et al.,Structure, 3:365-379 (1995).
Ding et al.,Nature Struct. Biol., 2:407-415 (1995).
El Dareer et al.,Drug Metabol. Dispos., 21:231-235.
Famighetti,1996 World Almanac and Book of Facts, World Almanac Books, Mahwah, NJ (1995), p. 840.
Fenichel et al.,Jour. Immunopharmacol., 2(4):491-508 (1980).
Gartner and Popovic,Techniques in HIV Research, Stockton Press, NY, pp. 69-63 (1991).
Gilbert et al.,Antiviral Res., 9:355-365 (1998).
Goldman et al.,Proc. Natl. Acad. Sci. USA, 88:6863-6867 (1991).
Merluzzi et al.,Science, 250:1411-1413 (1990).
Nanni et al.,Perspect. Drug Discov. Des., 1:129-150 (1993).
Nara and Fischinger,Nature, 332:469-470 (1988).
Nunberg et al.,J. Virol., 65:4887-4892 (1991).
Patel et al.,Biochem., 34:5351-5363 (1995).
Pauwels et al.,Antimicrob. Agents Chemother., 38:2863-2870 (1994).
Pauwels et al.,Nature, 343:470-474 (1990).
Pauwels et al.,Proc. Natl. Acad. Sci., USA, 90:1711-1715 (1993).
Richman,Agents Chemother., 37:1207-1213 (1993).
Romero et al.,Proc. Natl. Acad. Sci., USA, 88:8806-8810 (1991).
Smith et al.,Prot. Sci., 4:2203-2222 (1995).
Tantillo et al.,J. Mol. Biol., 243:369-387 (1994).
Warren et al.,immunopharmacol., I:269-276 (1979).
Yang et al.,Leukemia, 9:S75-S85 (1995).
Young,Perspect. Drug Discov. Des., 1:181-192 (1993).
Clark et al.,Meth. In Enzymol., 262:171-185 (1995).
Eymin et al.,Int. J. Cancer, 63(2):268-275 (1995).
Goker et al.,Arch Pharm. (Weinheim), 328(5):425-430 (1995).
Jacobo-Molina et al.,Biochem., 30(26):6351-6356 (1991).
Leteurtre et al.,Cancer Res., 52:4478-4483 (1992).
Leteurtre et al.,Biochem. Pharmacol., 49(9):1283-1290 (1995).
Solary et al.,Biochem. Pharmacol., 45(12):2449-2456 (1993).
Chimirri et al.,Il Farmaco, 51(4):279-282 (Apr., 1996).
Roth et al.,J. Med. Chem., 40:4199-4207 (Dec. 19, 1997).
Smith et al.,J. Med. Chem., 41(26):5272-5286 (1998).
Chimirri et al.,Abst. Il Congresso Italiano-Spagnolo di Chimica farmaceutica, Ferrara, Italy, Aug. 30-Sep. 3, 1995, ML20.
Michejda Christopher J.
Morningstar Marshall
Roth Thomas
Corless Peter F.
O'Day Christine C.
The United States of America as represented by the Secretary of
Travers Russell
LandOfFree
Substituted benzimidazoles as non-nucleoside inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted benzimidazoles as non-nucleoside inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted benzimidazoles as non-nucleoside inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3401980